UPMC has begun offering genetic testing for some people with heart problems to see whether a popular medication will be effective, with the potential of giving the hospital network a competitive advantage with consumers.

The simple blood test will determine whether the person has a genetic mutation that will keep the drug clopidogrel from working properly.

The anti-blood clotting medicine, which is sold as Plavix, will be offered to people who undergo the vessel-clearing procedure called heart catheterization at UPMC Presbyterian Hospital in Oakland.

The initiative is the first step in a bigger plan to use genetic testing to guide decisions about medication at the region’s dominant health care system, said Philip Empey, assistant professor of pharmacy and therapeutics at the University of Pittsburgh School of Pharmacy, who is leading the program.

Advertise with us

“We believe it should be a standard of care,” he said. “It’s not about one-size-fits-all medicine anymore.”

Not all medications work the same for all patients, something that has been attributed to individual genetic differences. Pharmacogenetics, which can be thought of as the marriage of genetics and decisions about medication, is a growing part of medical care that is tailored to the individual.

More than 700 patients annually are expected to be tested in the first year at UPMC Presbyterian. The test is voluntary and covered by major insurers. Studies have shown clopidogrel is ineffective in 30 percent of patients, with about 10 percent experiencing complications. Patients with a genetic variant that undermines clopidogrel’s effectiveness will be prescribed other medications.

Not everyone agrees the timing is right for large-scale testing for clopidogrel’s effectiveness. Although genetic testing for individual patients may be helpful, more research is needed to justify widespread testing of patients who are undergoing heart catheterization, said heart surgeon Srinivas Murali, who is medical director of the cardiovascular institute at Allegheny Health Network.

“These genetic tests are great. They look great on paper,” Dr. Murali said. “But if I practice medicine I want to know the proven benefits that we can expect.

Advertise with us

“We still need randomized controlled trials,” he said. “We still need more information.”

Kris B. Mamula: kmamula@post-gazette.com, 412-263-1699